A Rabbit Model Study of NanoFuse® Combination of DBM and 45S5 Bioactive Glass Rabbit spinal fusion models remain a well-established preclinical method for evaluating bone graft materials and biologics. In a space often driven by clinical claims and marketing narratives, studies like this provide an opportunity to examine underlying biological performance in a controlled setting. Findings: The study demonstrated that the FDA-cleared NanoFuse® combination of DBM and 45S5 bioactive glass outperformed bioactive glass alone in a rabbit model. Complementary alkaline phosphatase data further showed enhanced biological activity compared to DBM alone, supporting a combined—or potentially synergistic—effect of the formulation. In addition, NanoFuse combined with autograft performed comparably to autograft alone, indicating its potential utility as an adjunct in grafting applications. Taken together, these findings suggest that NanoFuse may provide improved biological performance relative to DBM alone. As the only FDA-cleared combination of DBM and bioactive glass, these data offer validation of its design and proposed mechanism. At the 4-week timepoint, NanoFuse demonstrated lower early fusion rates compared to autograft, indicating a slower early radiographic response. The overall pattern is consistent with a more gradual, dose-dependent bone formation profile, distinct from the rapid inductive effect associated with BMP-2. From a practical perspective, NanoFuse is designed to build on the clinical utility of DBM by enhancing performance while potentially reducing the volume of DBM required. Its ability to be combined with autograft also provides flexibility for surgical use.